OBJECTIVES: Because limited data are available on changes in direct costs (medical and prescription) and likelihood of health service utilization among employees treated with Interferon (IFN) â1a-IM for MS, the study aimed to assess the changes in direct costs and likelihood of health service utilization for persons with multiple sclerosis (MS) treated with IFN â1a-IM. METHODS: A health care claims database of US employees from 2001-2008 was used to identify patients with MS (2 IFN â1a-IM prescriptions [Rxs] or an IFN â1a-IM Rx MS diagnosis .X]). Employees with eligibility 6 months before and after their initial IFN â1a-IM Rx and no other disease-modifying therapies were included in the analysis. Non-parametric tests and t-tests were used to compare the mean and median direct medical costs and the likelihood of health service utilization before and after initiation of IFN â1a-IM. RESULTS: Data from 68 employees with MS that took IFN â1a-IM (42 employees with health service utilization data) were eligible for analysis. All direct medical cost changes were signifi cant (P 0.01). Mean medical costs decreased by $2872 (54%) from $5339 to $2467 and median costs decreased by $3691 (80%) from $4596 to $905. Signifi cant (P 0.05) decreases in the likelihood of health service utilization were noted for the following: 11.9% for emergency department from 11.9% to 0%, 23.8% for outpatient hospital from 64.3% to 40.5%, and 16.7% for "other" (including home-care, ambulance, mobile unit, and unknown) from 31.0% to 14.3%. Inpatient hospital care decreased non-signifi cantly (P 0.096) by 11.9% from 16.7% to 4.8%, while lab and offi ce claims stayed the same (7.1% and 92.9%, respectively). CONCLUSIONS: Direct medical costs decreased for IFN â1a-IM patients after therapy initiation, with reduced use of emergency department, inpatient and outpatient hospital care, and other services. These differences suggest the costs of Interferon â1a-IM are partially offset by medical care saving.
PND18 A HEALTH ECONOMIC EVALUATION OF TRANSANAL COLONIC IRRIGATION IN SPINAL CORD INJURY PATIENTS
Christensen P 1 , Andreasen J J 2 , Ehlers L 3 1 Aarhus University Hospital, Aarhus C, Denmark, 2 Coloplast A/S, Minneapolis, MN, USA, 3 University of Aarhus, Aarhus N, Denmark OBJECTIVES: To analyse the cost and cost-effectiveness of transanal colonic irrigation (TAI) using a self-administered system compared to conservative bowel management in spinal cord injury patients seen from a German perspective. METHODS: A cost effectiveness model was developed based on a randomised controlled multicentre trial conducted in [2003] [2004] [2005] , where 87 adult spinal cord injured patients with neurogenic bowel dysfunction were allocated to 10 weeks with either TAI or conservative bowel management. The sensitivity analysis was an extreme analysis based on confidence intervals, and estimates the results for best case and worst case scenarios. Cost variables (i.e. cost of constipation medication, treatment for urinary tract infections, products, labour of carer helping with bowel management and lost productivity of patients) were included and based on the clinical study results. Estimates of resources and unit costs were made for the German health care system. Effect variables were drawn from the same clinical trial. RESULTS: When comparing outcome measures at termination, TAI signifi cantly reduced symptoms of neurogenic bowel dysfunction. For a 2-day period, product-related costs were higher for TAI (€16 vs. €4), however, labour costs due to bowel management were lower (€6 vs. €9). For TAI, costs associated with urinary tract infections (€1 vs. €3) and patient time spent (€15 vs. €23) were reduced. Thus, the total cost to society was slightly lower when patients used TAI with a self-administered system (€38 vs. €39). The sensitivity analysis shows that costs may range from €33 to €46 for TAI and from €33 to €46 for conservative bowel management. CONCLUSIONS: Transanal colonic irrigation reduces the symptoms of neurogenic bowel dysfunction and results in a slightly lower total cost to society than conservative bowel management. The total cost results were found to be robust in the sensitivity analysis.
PND19 EXPLORATORY ANALYSES AND MODELING FOR RELATIVE COSTS OF INFANTS WITH HYDROCEPHALUS
Wilburn D University of Louisville, Louisville, KY, USA OBJECTIVES: Hydrocephalus is a disorder where cerebrospinal fl uid (CSF) is unable to drain effi ciently from the brain. Infants affl icted often present with enlarged heads, and multiple complications can occur. The standard treatment is the relatively dangerous, complicated, and expensive surgical insertion of a shunt system to drain the fl uid. It is the purpose of this project to explore possible contributing variables to the presence of the disease in infants and its relative costs. METHODS: Inpatients one-year-old or younger affl icted with hydrocephalus and an equally sized control group were extracted from the National Inpatient Sample (NIS) provided by the Agency for Healthcare Research and Quality (AHRQ). The statistical data modeling software, SAS, was used for calculation of summary statistics, kernel density estimation, logistic and linear regression, and production of fi gures and charts. Exploratory data analysis was used to examine the data in detail. RESULTS: It was determined that younger infants show higher mortality rates; additionally, males are more likely to present with hydrocephalus and cost slightly more on average than females despite the distribution curves for length of stay appearing virtually identical between genders. Diagnoses and procedures expected for non-hydrocephalic infants showed negative correlation in the logistic model. The linear model showed that low birth-weight signifi cantly impacted length of stay when also present with hydrocephalus. Additionally, affl iction with hydrocephalus at admittance was strongly correlated with length of stay but not total costs, implying an impact on recovery time, but not additional treatments. CONCLU-SIONS: The costs of health care in America are constantly rising, and infants often incur greater costs due to the need for sophisticated and advanced treatments. Hydrocephalus clearly exacerbates medical costs, and should warrant further study. Exploratory analysis can fi nd important and relevant information about the disease. Cholinesterase inhibitors (ChEIs), including rivastigmine, donepezil, and galantamine, when taken as prescribed impact mild to moderate cognitive impairment due to Alzheimer's disease (AD). Optimal compliance and persistence with oral ChEIs are important to realize the benefi cial outcomes of treatment initiation. The current study quantifi es compliance and persistence rates of oral ChEIs in an effort to understand the unmet therapeutic needs among patients with AD. METHODS: A claims analysis was conducted from January 2004 through December 2006 using the MedStat MarketScan database. Patients with 18 months of continuous insurance coverage, newly initiated on an oral ChEI (no use in prior 6 months), 12 months follow up (F/U), and 1 diagnosis of AD (ICD-9 331.0, 290.0-290.3, 294.10-294.11) were included. Compliance was estimated using medication possession ratio (MPR) during the fi rst 12 months of F/U. Persistence was defi ned as continuous drug use without a gap of 30 days between medication refi lls at any time after treatment initiation. Proportion of compliant patients (MPR 0.8) and Kaplan-Meier rates of persistence were calculated. RESULTS: Of the 4957 study patients, mean age was 80.3 years and 58.4% were females. A total of 385 (7.8%) patients switched ChEI during the fi rst year of F/U. Mean (SD) number of refi lls per patient was 7.5 (3.7) and mean (SD) duration of gap between refi lls was 20.7 (31.9) days. Mean (median) MPR and proportion of compliant patients were 0.74 (0.83) and 71%, respectively. Kaplan-Meier rates of persistence after 3, 6, 12, and 24 months were 79.0%, 60.3%, 40.1%, and 21.4%, respectively. CONCLUSIONS: Based on real-world data from a large cohort of AD patients initiated on ChEI, less than 50% were persistent on therapy during the fi rst year following ChEI treatment initiation. Further research is warranted to determine whether transdermal patches might improve the persistence on ChEI therapy.
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PND20 COMPLIANCE AND PERSISTENCE OF ORAL CHOLINESTERASE INHIBITORS IN PATIENTS WITH ALZHEIMER'S DISEASE
PND21 FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
Meletiche DM 1 , Kozma C 2 , Dickson M 3 1 EMD Serono, Inc, Rockland, MA, USA, 2 University of South Carolina, West Columbia, SC, USA, 3 University of South Carolina, Columbia, SC, USA OBJECTIVES: Early initiation of therapy with disease-modifying drugs (DMDs) is important for the successful management of multiple sclerosis (MS). This study examined the time to fi rst use of DMDs in newly diagnosed MS patients. METHODS: In a post hoc analysis, newly diagnosed MS patients were identifi ed using a national managed care database. Patients, aged 18 to 65 years, received their fi rst MS diagnosis between July 1, 2000 and December 31, 2005 (index date), and were continuously eligible for 6 months prior to the index date and 24 months after the index date. During the 24-month postindex period, subjects received 1 DMD (interferon beta [IFN ]-1a intramuscular, IFN -1b, glatiramer acetate, IFN -1a subcutaneous, or natalizumab). The analysis did not include patients whose fi rst DMD prescription was given after the study end date (December 31, 2007), or those who had used DMD in 6 months preceding their fi rst MS diagnosis. RESULTS: A total of 2522 MS patients (76.3% women) met the inclusion criteria for the study. The mean standard deviation patient age was 42.1 9.7 years. Most patients (47.9%) were from the Midwest, refl ecting the national database sampling. The median time from fi rst MS diagnosis to fi rst DMD use was 61.0 days; mean time was 140.2 171.9 days. When the time to fi rst treatment was examined in 30-day increments, the results showed that 27.8% received their fi rst DMD in 30 days, 49.0% in 60 days, 59.6% in 90 days, and 74.2% in 180 days. One of every 4 patients (25.8%) did not initiate DMD for 180 days following their fi rst diagnosis. CONCLUSIONS: The fi ndings of this analysis suggest that newly diagnosed MS patients often delay initiating DMD therapy.
